[Federal Register Volume 81, Number 64 (Monday, April 4, 2016)]
[Notices]
[Page 19186]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-07626]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting for the initial review of
applications in response to Funding Opportunity Announcement (FOA),
RFA-CE-16-003, Research on Prescription Opioid Use, Opioid Prescribing,
and Associated Heroin Risk.
Time and Date: 8:30 a.m.-5:00 p.m., EDT, April 27-28, 2016
(Closed).
Place: Atlanta Marriott Century Center, 2000 Century Blvd. NE.,
Atlanta, Georgia 30345.
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters for Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``Research on Prescription Opioid Use, Opioid Prescribing, and
Associated Heroin Risk'', FOA RFA-CE-16-003.
Contact Person for More Information: M. Chris Langub, Ph.D.,
Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F-80,
Atlanta, Georgia 30341, Telephone: (770) 488-3585, [email protected].
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2016-07626 Filed 4-1-16; 8:45 am]
BILLING CODE 4163-18-P